2021
Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial
Dwyer JB, Landeros-Weisenberger A, Johnson JA, Londono Tobon A, Flores JM, Nasir M, Couloures K, Sanacora G, Bloch MH. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. American Journal Of Psychiatry 2021, 178: 352-362. PMID: 33653121, DOI: 10.1176/appi.ajp.2020.20010018.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionDepression Rating ScaleIntravenous ketamineClinical trialsAdolescent treatment-resistant depressionAdult treatment-resistant depressionPlacebo-controlled clinical trialSignificant short-term efficacySerious adverse eventsPrimary outcome measureSingle intravenous infusionChildren's Depression Rating ScaleCrossover clinical trialShort-term efficacyMajor depressive disorderSingle ketamine infusionSymptoms 24 hoursLater time pointsKetamine’s safetyAdverse eventsAntidepressant medicationKetamine infusionPediatric populationSignificant morbidityIntravenous infusion
2019
N-Acetylcysteine for Pediatric Obsessive-Compulsive Disorder: A Small Pilot Study
Li F, Welling MC, Johnson JA, Coughlin C, Mulqueen J, Jakubovski E, Coury S, Landeros-Weisenberger A, Bloch MH. N-Acetylcysteine for Pediatric Obsessive-Compulsive Disorder: A Small Pilot Study. Journal Of Child And Adolescent Psychopharmacology 2019, 30: 32-37. PMID: 31800306, PMCID: PMC7133418, DOI: 10.1089/cap.2019.0041.Peer-Reviewed Original ResearchConceptsCY-BOCS total scoreN-acetylcysteineYale-Brown ObsessiveTotal scorePlacebo groupNAC groupStudy populationBenefit of NACPlacebo-controlled clinical trialSymptom severityEffect of NACMild adverse eventsOCD symptom severityLarger study populationPediatric obsessive-compulsive disorderSmall pilot studyChildren's Yale-Brown ObsessiveStudy medicationAdverse eventsPrimary outcomeGlutamate dysfunctionObsessive-compulsive disorderWeek 12Future trialsNAC treatment
2017
Efficacy of antipsychotics for irritability and aggression in children: a meta-analysis
van Schalkwyk GI, Lewis AS, Beyer C, Johnson J, van Rensburg S, Bloch MH. Efficacy of antipsychotics for irritability and aggression in children: a meta-analysis. Expert Review Of Neurotherapeutics 2017, 17: 1045-1053. PMID: 28847182, DOI: 10.1080/14737175.2017.1371012.Peer-Reviewed Original ResearchConceptsDegree of sedationSubgroup analysisDiagnostic indicationsOverall dose effectEfficacy of risperidoneStratified subgroup analysisEfficacy of antipsychoticsIndividual antipsychotic agentsChoice of agentRange of diagnosesSpecific medicationsAntipsychotic efficacyAntipsychotic agentsAntipsychotic doseClinical dataOverall effect sizeAntipsychoticsNegative psychosocial outcomesIrritabilityPsychosocial outcomesEfficacyDiagnosisDose effectSedationRisperidonePredictors of Long-Term Risky Driving Behavior in the Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity Disorder
Johnson JA, Jakubovski E, Reed MO, Bloch MH. Predictors of Long-Term Risky Driving Behavior in the Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity Disorder. Journal Of Child And Adolescent Psychopharmacology 2017, 27: 747-754. PMID: 28771386, PMCID: PMC5651934, DOI: 10.1089/cap.2017.0025.Peer-Reviewed Original ResearchConceptsAttention-deficit/hyperactivity disorderRisky driving behaviorsMultimodal Treatment StudyHyperactivity disorderDriving behaviorParental protectivenessLow parental monitoringParental stress levelsTreatment studiesParental stressParental monitoringConduct disorderHigh-risk childrenStepwise logistic regression analysisLogistic regression analysisYears of ageStepwise logistic regressionDiscriminative predictorsHigh-risk behaviorsParental levelPredictors of Long-Term School-Based Behavioral Outcomes in the Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity Disorder
Reed MO, Jakubovski E, Johnson JA, Bloch MH. Predictors of Long-Term School-Based Behavioral Outcomes in the Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity Disorder. Journal Of Child And Adolescent Psychopharmacology 2017, 27: 296-309. PMID: 28253029, PMCID: PMC5439457, DOI: 10.1089/cap.2015.0168.Peer-Reviewed Original Research